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Mistletoe in the treatment of malignant melanoma
Malign melanomun tedavisinde ökse otunun yeri
Esin Sakallı Çetin1, Pınar Aslan Koşar2, Nurten Özçelik2
ÖZET
Melanoma melanositlerden köken alan malign tümördür. 
Deri  kanserleri  içinde  3.  sıklıkta  görülen  melanoma  en 
fazla ölüme neden olan kanser tipidir. Malign melanomu, 
diğer solid tümörlerden ayıran belirgin özellikleri, kemo-
terapötik ajanlara gösterdiği intrinsik direnç ve hastalık 
seyrinin değişkenliğidir. Bu özellikler, malign melanomda 
cerrahi dışı tedavi modellerinin geliştirilmesini ve standart 
hale getirilmesini engellemektedir. Metastatik malign me-
lanom  tedavisinde  kullanılan  çok  sayıda  kemoterapötik 
ajan olmasına rağmen bu ajanlar ile yapılan adjuvan te-
davi çalışmalarında sağ kalım avantajı gösterilememiştir. 
Malign melanomun farklı klinik seyir göstermesi nedeniy-
le, hastalığın immun sistem ile yakından ilişkili olabileceği 
düşünülmektedir.  Bu  nedenle  immunomodulatör  tedavi 
modelleri geliştirilmiştir. Ökse otunun dendritik hücrelerin 
sayısını ve aktivitesini artırmak suretiyle immün sistemi 
uyardığı ve böylece malign melanomlu hastada tümör bü-
yümesi ve metastazı üzerine etkili olduğu gösterilmiştir. 
Derlemede malign melanomun komplementer tedavisin-
de ökseotunun rolünün anlaşılmasına yönelik güncel ge-
lişmeler özetlenmiştir. 
Anahtar kelimeler: Malign melanom, ökse otu, viscum 
album
ABSTRACT
Malignant melanoma is a malignant neoplasia drives from 
melanocytes.  Malignant  melanoma,  the  most  causing 
death, is seen in the third place at skin cancer. Malignant 
melanoma  shows  intrinsic  resistance  to  chemothera-
peutic agents and variability in the course of the disease 
which are distinct features separating from other solid tu-
mors. These features prevent the development and stan-
dardization of non-surgical treatment models of malignant 
melanoma. Although there is a large number of chemo-
therapeutic agents used in the treatment of metastatic 
malignant  melanoma,  it  hasn’t  been  demonstrated  the 
survival advantage of adjuvant treatment with chemother-
apeutic agents. Because of the different clinical course of 
malignant melanoma, the disease is thought to be closely 
associated  with  immune  system.  Therefore,  immuno-
modulatory  therapy  models  were  developed.  Mistletoe 
stimulates the immune system by increasing the number 
and activity of dendritic cells, thus it has been shown to 
effect on tumor growth and metastasis of malignant mela-
noma patient. Outlined in this review are the recent de-
velopments in the understanding the role of mistletoe as 
a complementary therapy for malignant melanoma. J Clin 
Exp Invest 2014; 5 (1): 145-152
Key words: Malignant melanoma, mistletoe, Viscum al-
bum
INTRODUCTION
Malignant melanoma is the malignant transforma-
tion  of  melanocytes,  the  pigment  producing  cells 
found in the skin, eye, inner ear, and leptomenin-
ges, of which the skin is the most common site for 
melanoma development [1]. Superficial spreading, 
nodular,  and  acral  lentiginous,  of  which  nodular 
melanomas have the worst prognosis are three his-
tologic types of malignant melanoma [2]. Malignant 
melanoma is the most serious type of skin cancer 
with the fastest increasing incidence and survival 
of patients with distant metastases is generally less 
than one year [3]. The treatment of early-stage ma-
lignant melanoma is possible with wide surgical exci-
sion and regional lymph node curettage [4]. Despite 
intensive research, no curative treatment exists for 
metastatic malignant melanoma [5]. Conventional 
chemotherapy or combination of radio and chemo-
therapy have yet no broadly successful therapies 
and have not led to any considerable prolongation 
of survival [6]. As scientific medicine have been dis-
appointingly ineffective to offer for melanoma pa-
tients with the threat of metastatic disease, the most 
of the patients turn to supplementary therapy such 
as aqueous mistletoe (Viscum album, VA) extracts Çetin et al. Mistletoe in malignant melanoma 146
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[7]. The mechanism underlying the anti-tumoral ac-
tivity of mistletoe preparations has been poorly un-
derstood. Moreover, the proposed mechanisms in-
clude induction of apoptosis of tumor cells and lym-
phocytes, inhibition of angiogenesis and stimulation 
of the cellular compartment of the immune system, 
raising the number and the activity of natural killer 
(NK) cells, dendritic cells (DCs) and granulocytes 
[8-11]. This review investigates the role of the mis-
tletoe preparations on the reduction of melanoma 
growth and number of metastases in experimental 
models [8,12-17] with the enhancement of DC in-
filtration and apoptosis induction in the melanoma 
cells. In addition, a case report presents in litera-
ture, emphasized on a complete remission of malig-
nant melanoma with mistletoe treatment [18]. These 
findings suggest that mistletoe brings new clinical 
perspectives as a complementary therapy for ma-
lignant melanoma.
Epidemiology
Malignant melanoma is an aggressive skin disease 
with high incidence mortality. According to a World 
Health  Organization  estimate,  there  are  132,000 
new cases of melanoma per year worldwide [19]. 
The  American  Cancer  Society  (ACS)  estimates 
68,130 new cases of melanoma in the United States 
in 2010 with 8,700 deaths, mostly male deaths, con-
stituting a serious public health issue [20]. Malig-
nant melanoma has become a cancer with a major 
socioeconomic impact because of a high mortality 
rate of metastatic disease and a relatively high in-
cidence among adolescents and young adults [21]. 
In addition to its incidence and propensity to affect 
young adults, melanoma is a major health problem 
with high metastatic potential toward the skin, lung, 
brain  and  the  gastro-intestinal  tract,  aggressive 
clinical behavior and notable resistance to currently 
available  chemotherapeutic  and  immunological 
treatments [22]. The higher incidence of melanoma 
is also closely associated with the some host factors 
important risk factors for melanoma such as skin 
type,  presence  of  dysplastic  nevi,  degree  of  pig-
mentation, susceptibility to ultraviole radiation and 
episodes of sunburn, immunosuppression, certain 
melanoma susceptibility genes and family history of 
the disease [23]. The molecular mechanisms under-
lying the melanoma development remain unclear, 
even though there is advances in the knowledge of 
risk factors for melanoma [22].
The treatment of malignant melanoma
The  therapeutic  management  of  malignant  mela-
noma is quite challenging issue. It requires care-
ful clinical examination, skin biopsies and precise 
immuno-histological analysis. After tumor staging, 
medical or surgical intervention is made. Survival 
has been found to be strongly correlated with thick-
ness  and  ulceration  of  primary  tumour  [24].  For 
patients with thicker than 4 mm melanoma, 5-year 
survival rate is approximately 30-50% (17). There-
fore, early diagnosis is the most critical step in the 
disease management. For metastatic disease the 
prognosis is poor, with a 5-year life expectancy of 
<10% and a median survival of 6-8,5 months. Che-
motherapy  for  advanced  disease  remains  unsat-
isfactory [25]. Since melanoma is one of the most 
resistant malignancy to medical therapy among the 
solid tumours, therefore early diagnosis and surgi-
cal removal of the primary tumor is virtually the only 
curative approach currently available [26]. In 2011, 
for advanced malignant melanoma treatment, the 
Food and Drug Administration (FDA) and the Euro-
pean Medicines Agency (EMA) have approved new 
drugs, ipilimumab and vemurafenib [27]. However, 
time  is  needed  to  conclude  whether  these  drugs 
can be replaced with dacarbazine (DTIC), a drug 
used for over 30 years in the therapy of metastatic 
melanoma, even if the response rate was only 10-
15%, so the number of living is less than 6 years 
[26].  When  all  survival  rates  were  evaluated,  it 
was  found  that  there  was  no  difference  between 
the single use or combination therapies, including 
CVD (sisplatin, vinblastin, DTIC) and PVB (sispla-
tin,  vinblastin,  bleomisin).  The  response  rates  of 
these combination therapies at phase II studies is 
20-40%, the tumor response rate is <5% and <2% 
for log-term. As a result, the adjuvant treatment with 
chemotherapeutic agents seems to be not effective 
for survival [28]. 
Because malignant melanoma shows a differ-
ent clinical course, it is thought to be closely associ-
ated with the immune system. Therefore, immuno-
modulatory therapy models, interferon alpha (INF-α) 
and interleukin-2 (IL-2), were developed [29]. The 
respond rate of these therapies is 10-20 % and long 
time remission is seen in only 3-5 % of the cases. 
Also the findings of several randomized controlled 
trials  (RTCs)  conducted  on  the  use  of  INF-α  are 
conflicting in terms of therapeutic efficiency [30-32]. 
Most importantly, so far there has not been demon-
strated any overall survival (OS) benefit, even after 
adjustment for quality of life incorporating patient’s 
values for the toxic effects of INF-α treatment and 
melanoma recurrence [33]. Therefore, routine use 
of INF-α accompanied by clinically relevant toxic ef-
fects and represents a substantial economic burden 
for the health-care system is fostering a continues 
debate among oncologists [34-36].Çetin et al. Mistletoe in malignant melanoma 147
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Dendritic cell-based immunotherapy of 
malignant melanoma
Dendritic cells (DC) are also an important tool for 
tumor-antigen-specific  immunotherapy  of  cancer 
because of their critical role in mounting a specif-
ic immune response where their intratumoral and 
peritumoral density as well as their functional status 
are correlated with clinical staging of the disease 
and patient’s survival [24-37]. DC originates from 
hematopoietic stem cells with in the bone marrow. 
Under  phsiological  conditions  both  myeloid  and 
lymphoid  precursors  differentiate  into  immature 
dendritic cells. In peripheral tissues, upon the up-
take of antigen, receiving danger signals or in the 
context  of  inflammation,  DC  undergo  maturation 
process and migrate to the secondary lymphoid or-
gans [37]. This maturation process is characterized 
by increased surface expressing of antigen present-
ing surface molecules like major histocompatibility 
complexes (MHC class I interacts with CD8+ cells 
whereas MHC class II interacts with CD4+ cells) 
and co-stimulatory molecules such as CD-54, CD-
58, CD-83, CD-80 and CD-86 and secrete several 
pro-inflammatory  cytokines  (IL-2,IL-4,IL-6,  IL-12, 
TNF-α etc.) [19,38]. (Figure 1) As a result of this 
maturation process, DC are well equipped to acti-
vate naive T cells; CD 8+ T cells differentiate into cy-
totoxic T cells (CTL) while CD+4 T cells differentiate 
into T helper-1 (Th1) or T helper-2 cells (Th2) which 
interact with macrophages and B cells, respective-
ly, thus providing a link between the adaptive and 
innate immune system in the secondary lymphoid 
organs [19,37]. A Th1 immune response and also 
CTL activation are the goal of utilizing DC as a can-
cer vaccine in order to eliminate tumor [19]. DC are 
not just regulators of the immune response, but also 
maintenance of the immune tolerance in the thymus 
and secondary lymphoid organs. DC present self 
antigen (Ag) to develop immune cell and induce de-
letion of autoreactive T cells result in self tolerance 
depending  on  the  status  of  the  immune  system: 
steady state versus infection. This situation very im-
portant for DC-based anti-tumor immunotherapies 
to control DC differentiation to prevent undesirable 
effects of vaccination such as tolerance induction 
by tolerogenic DC [29]. Moreover, immune evasion 
of tumor cells by down-regulation of surface or in-
tracellular molecules are also limiting factors for the 
efficiency of the DC-based vaccination in tumor pa-
tients. The other limiting factors are the secretion 
of soluble immunosuppressive cytokines by tumor 
cells that convert immature into tolerogenic DC and 
presence  of  naturally  occurring,  antigen-specific 
regulatory T cells. However, DC-based vaccination 
led to regression of individual metastases but no 
complete remission [24]. 
Mistletoe and malignant melanoma
In studies using mistletoe preparations, regression 
of tumor metastases and complete remission was 
observed  in  experimental  models  with  increasing 
the number and activity of DC (8,12-17). Mistletoe 
preparations,  the  most  common  form  of  comple-
mentary/alternative cancer therapy, are used often 
the protocols of adjuvant treatment with standard 
chemotherapy or radiotherapy. This combined treat-
ment increased the cancer patient’s quality of life 
with stimulating immune system [39].
Mistletoe is a semiparasitic plant of the Loran-
thacea family that grows wild on deciduous hard-
wood trees like the apple, oak, ash, and elm (var al-
bum), or on coniferous tress like pine and fir (Pinus 
and Abies varieties) [40]. Mistletoe has been used 
in tradional medicine since ancient times, especial-
ly used by the Druids and ancient Greeks, and it 
appears in legend and folklore as a panacea [41]. 
Extracts from mistletoe have been used, as a seda-
tive,  vasodilator,  diuretic,  analgesic,  cardiotonic, 
anti-spasmolytic,  therapeutically  aganist  various 
diseases including cancer, atherosclerosis, hyper-
tension,  dizziness,  chorea,  hysteria,  periarthritis, 
spondylitis and arthritis [42-44]. 
Mistletoe  was  firstly  used  as  an  anticancer 
agent in 1917 by Steiner and Wegman, founders of 
anthnoposophic medicine. Moreover, it has became 
the most commonly used form of adjuvant cancer 
therapies in Europe from 1970s. Particularly in Ger-
many, Austria and Switzerland, mistletoe prepara-
tions are most frequently used in the treatment of 
cancer patient [45,46]. Commercially available ex-
tracts, preperad from Viscum album L., are market-
ed under a variety of brand names, including Isca-
dor (Iscar), Eurixor, Helixor, Isorel (Vysorel), Iscu-
cin, Plenosol (Lektinol) and Abnova-viscum [46,47]. 
Commercial preparations are widely differ with re-
gard to their chemical compositions that depens on 
the species of the host tree (apple, elm, oak, pine, 
poplar and spruce) and the time of year harvested, 
lectin content the main active ingredient, and meth-
ods  of  preparations,  including  alcoholic-aqueous 
extraction and fermentation of aqueous extract with 
lactic acid bacteria [48].
The fermented aqueous exracts of mistletoe are 
biologically and biochemically standardized. One of 
these preparations is Iscador, which is marketed as 
Iscador M (from apple trees) contains 250 ng total 
lectins/ml, Iscador Qu (from oak trees) contains 375 
ng  total  lectins/ml  whereas  Iscador  P  (from  pine Çetin et al. Mistletoe in malignant melanoma 148
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trees)  contains  only  trace  amount  of  lectins  [12]. 
The  antiproliferative  effects  of  Iscador  M  special, 
Iscador Qu special and Iscador P were investigated 
in a panel of 16 human tumor cell lines comprising 
nine different tumor types, central nervous system, 
gastric, non-small cell lung, mammary, prostate, re-
nal, uterine cancer cell lines as well as hematologi-
cal malignancies and melanomas. While Iscador M 
special and Iscador Qu special showed antitumor 
activity with a more than 70% growth inhibition in 
the mammary cell line, Iscador P showed no prolif-
erative activity [12]. Eurixor, an unfermented aque-
ous exract of mistletoe, harvested from poplar trees, 
is standardized to contain a spesific amount of ML-I. 
Helixor, unfermented aqueous exract of mistletoe is 
marketed as Helixor A (from spruce trees), Helixor 
M (from apple trees) and Helixor P (from pine trees) 
[49].
Mistletoe gained attention as a potantial anti-
cancer agent because of their immunomodulatory 
and cytotoxic properties [9,39,50-53]. Mistletoe ex-
tracts stimulate the immune system non-spesifically, 
by increasing the number and activity of T lympho-
cytes, B lymphocytes, dendritic cells, natural-killer 
(NK)  cells,  neutrophils  and  activating  phagocytic 
activity  of  granulocytes  with  subsequent  release 
of cytokines such as tumor necrosis factor alpha 
(TNF-α),  interferon  gamma  (IFN-γ),  granulocyte 
macrophage  colony-stimulating  factor  (GM-CSF), 
interleukin-1 (IL-1), IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, 
IL-12. All of these immune mechanisms, if stimulat-
ed, can induce tumor cell lysis [50-53].
From the various components found in most 
mistletoe  extracts,  lectins,  alkaloids,  viscotox-
ins  and  polysaccharides,  several  enzymes,  pep-
tides (such as viscumamide), amino acids, thiols, 
amines,  cyclitoles,  lipids,  phytosterols,  triterpines, 
flavonoids, phenylpropanes and minerals, the most 
active compounds in cytotoxity and immuno-mod-
ulatory effects are lectins and viscotoxins [54-56]. 
The three mistletoe lectins (MLs) Ml-I, -II, -III are the 
main therapeutic components of mistletoe exracts 
[57]. The antitumor effect of lectins is though to be 
induction of the death of tumor cells via binding of 
B-chain  carrying  the  carbohydrate-binding  site  to 
the target cell surface, which enables the protein to 
enter the cell, and inhibition of protein synthesis by 
A-chain removing an adenine residue from the 28S 
RNA of the 60S subunit of the ribosome due to its ri-
bosome-inactivating properties (Rip type II) [58,59].
Of the three MLs, ML-I is the widely investigat-
ed in the immunomodulation and anticancer studies 
[53,60,61]. Malignant melanoma cells represent an 
ideal target for ML-I cytotoxic therapy because pri-
mary malignant melanomas and their metastases 
express particularly high numbers of ML-I binding 
sites [62,63]. A highly significant antiproliferative ef-
fect of ML-I via the induction of apoptosis on ma-
lignant melanoma cells was demonstrated in vitro 
experiments [14,64]. One of these processes was 
observed by Thies A. et al. (2005) that all three MLs 
inhibited melanoma cell proliferation in a dose-de-
pendent manner starting at very low ML concentra-
tions (0.001-100 ng/ml) with ML-I being the most 
cytotoxic lectin on ultra sensitive cell line MV3 at 
1x10-13 ng ML-I/ml [13]. In addition their obtained 
in vitro results, they (Thies et al. 2008) established 
a  clinically  relevant  human  melanoma  xenograft 
scid mouse model to analyze the effect of ML-I on 
melanoma growth and spread [15]. Because of the 
expressing high number of ML-I binding sides and 
the being ultra sensitive to ML-I cytotoxicity in vitro 
(Thies et al. 2005), the human melanoma cell line 
MV3 was used to model a targeted therapy in vivo 
to analyse apoptosis rates, the number of infiltrat-
ing DCs and vascular counts in primary melanomas 
(PM) and their spontaneous lung metastases (LM) 
[15].  Purified  ML-I  administered  at  low-dose  (30 
ng ML-I per kg) daily for 19 days reduced both tu-
mor weight by 35% and the number of LMs by 56 
% compared to control mice. They demonstrated a 
significant direct cytotoxic effect of ML-I on malig-
nant melanoma cells in the PTs and LMs by assess-
ing apoptotic rates of the malignant melanoma cells. 
ML-I  increased  apoptosis  rates  in  the  melanoma 
cells of PTs at all doses, however, apoptosis rates 
didn’t increase in parallel to increased ML-I concen-
trations as one would have expected from their in 
vitro data (Thies et al, 2005) [15]. The direct cyto-
toxic effect of ML-I seems to play only a minor role 
in the antitumorigenic effect in vivo because no sig-
nificant reduction in tumor weight was noted in the 
higher ML-I doses, all of these results demonstrate 
the importance of in vivo models [33]. The number 
of tumour-infiltrating DCs was examined to evalu-
ate the importance of immunomodulatory effects of 
ML-I on melanoma growth and spread. Low-dose 
lectin-I treatment significantly raised the total num-
ber of DCs and also protected them against apop-
tosis in PT [15]. 
Clinical studies with mistletoe lectins demostrat-
ed that mistletoe preparations stimulate the cytokine 
secretion and monocyte function, the precursors of 
DCs [65]. The previous in vitro studies by Stern et 
al. indicated that aquous mistletoe extract induced 
the maturation of DCs with an increased expression 
of  co-stimulatory  molecules  CD80,  CD86  as  well 
as antigen presenting molecules HLA class I and 
II [66]. Like these studies, Elluru et al. demostrated Çetin et al. Mistletoe in malignant melanoma 149
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that mistletoe QuSpez induced maturation and acti-
vation of DCs presented with increased expression 
of co-stimulatory molecules CD40, CD80 and CD86 
and secretion of inflammatory cytokines IL-6 and 
IL-8 [8]. Duong Van Huyen et al. demonstrated that 
antitumoral effects of mistletoe extract (Iscador Qu 
FrF) are mediated by IL-12 dependent pathway, in-
vestigated on B16F1 melanoma implanted mice. In 
IL-12-deficient strain of mice, the inhibition of mela-
noma growth were abrogated by mistletoe [16]. An-
titumor properties of IL-12 include an enhancement 
of Th1, CD8+CTL cells (19) and NK-cell functions 
[67].  Preliminary  results  indicated  that  mistletoe 
extract  treatment  induces  an  increase  in  the  NK 
cells activity [8,68]. Furthermore, DCs educated by 
mistletoe Qu Spez stimulated CD4+T cells and ac-
tivated melanoma antigen Melan-A/MART-I-specific 
M77-80 CD8+T cells as sugessed by the increased 
levels of secretion of TNF-α and IFN-γ in a allogenic 
mixed lymphocyte reaction [8]. In addition, an in-
crease in CD4 + T and CD8 + T cells were reported 
by Gardin (2008) in immunological tests carried out 
before and after mistletoe treatment in four cancer 
patients, hodgkin disease, breast cancer and mul-
tiple myeloma who received seven subcutaneous 
doses of mistletoe 20 mg, twice weekly [69].
In contrast to the effects of ML-I on primary tu-
mours (PTs), there was not a significant induction 
of apoptosis in the melanoma cells in the lung me-
tastases (LMs) at any ML-I concentration [15]. The 
significant reduction of LMs at low-dose ML-I (30 ng 
ML-I per kg) seemed to be the consequence of suc-
cessful reduction of the PT mass due to ML-I treat-
ment because correlation analyses revealed a high-
ly significant positive correlation between the weight 
of the PTs and the number of corresponding LMs 
in all groups [15]. The reduction of the number of 
LMs but not of their size underlines the considerably 
stronger cytotoxic effect on circulating tumour cells, 
which are more prone to apoptosis induction than 
cells within the PT [70], while in established metas-
tases cytotoxic effects of ML-I seem to play a mi-
nor role [15]. The stimulation of the immune system 
plays the prominent role in its antimelanoma effect 
via induction of maturation and activation of tumor 
infiltrating DCs in the PTs of all treatment groups 
since DC express high number of ML-I-binding sites 
[15,17].
Figure 1. The maturation process of dendritic cells, co-stimulatory molecules an pro-inflammatory cytokines
A CASE REPORT
The complete remission of malignant 
melanoma with mistletoe treatment
Clinical benefit from adjuvant treatment with a stan-
dardized mistletoe extract in patient with malignant 
melanoma was also demonstrated by Kirsch (2007) 
[18]. The complete tumor remission was achieved 
with  twice-weekly  subcutaneous  administration  of 
Iscador®M  (Weleda  AG,  CH-Arlesheim,  Switzer-
land). A 68 years-old male patient with one malignant 
melanoma at the upper part of the right arm first di-
agnosed in 1992. In November 1999, another mela-
noma was surgically removed at the patient’s right Çetin et al. Mistletoe in malignant melanoma 150
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shoulder, which the histologic examination revealed 
nodular melanoma, stage IIA (pT3, pN0, M0). After 
discovery of the second melanoma and surgical re-
section, treatment with standardized mistletoe ex-
tract (Iscador, M; Weleda AG, CH-Arlesheim, Swit-
zerland) was initiated in November 1999 by the pa-
tient’s general practitioner. During the course of the 
mistletoe therapy, axillary removal of 8 lymph nodes 
became necessary, 3 of which proved to be meta-
static. In September 2001, first signs of a defined 
solitary liver metastasis with a maximum diameter 
of 2 cm in an area next to segments IV and V were 
detected during an abdominal ultrasound examina-
tion. Moreover, this finding was also confirmed by 
further sonographic examinations. The solitary liver 
metastasis was not resected, nor was classical an-
titumor  treatment  (chemotherapy  or  radiotherapy) 
initiated. The patient continued subcutaneous treat-
ment with Iscador M after dose adaptation to 2 mg 
twice weekly (0.2 mL of a 10-mg vial) from October 
2001 until November 2005. By June 2002, complete 
remission of the liver metastasis was diagnosed by 
liver ultrasound examination. No further metastases 
were discovered in May 2006. The use of low-dose 
Iscador as the sole postoperative modality for the 
adjuvant treatment of metastatic melanoma was ex-
tremely effective and very well tolerated in this pa-
tient. It achieved complete response and absence 
of all complaints [18]. These findings are in accor-
dance with in vivo studies showing that mistletoe 
treatment had no negative influence on the vitality, 
behaviour  and  physiological  responses,  appear-
ance, or food and water habits of the animals at any 
dosage [15].
In conclusion, despite improvements in chemo-
therapy and immunotherapy, therapeutic quest of 
the malignant melanoma continues. The early stage 
malignant melanoma is curable with surgical resec-
tion. However, prognosis is poor for patients with 
advanced melanoma. Malignant melanoma shows 
intrinsic  resistance  to  chemotherapeutic  agents 
and variability in the course of the disease which 
are distinct features separating from other solid tu-
mors. These features prevent the development and 
standardization of non-surgical treatment models of 
malignant melanoma. These circumtances call for 
new  treatment  modalities  for  melanoma  patients; 
one potential treatment strategy under evaluation 
is  mistletoe,  a  natural  immunomodulator,  based 
treatment.  Because  of  apoptosis  induction  in  the 
melanoma cells and simultaneously enhancement 
the number of DCs, mistletoe treatment could have 
important impact in future melanoma therapy.
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